Sabon Fata ga Ciwon Chemotherapy-B-Cell Lymphoma Mai Rage Ragewa: Maganin CAR-T Ya Nuna Sakamako Mai Kyau

Binciken da aka yi kwanan nan ya nuna yuwuwar maganin ƙwayoyin cuta na Chimeric Antigen Receptor (CAR)-T wajen magance marasa lafiya da ke fama da cutar sankarar bargo ta B-cell, musamman waɗanda suka yaɗu a manyan wurare, musamman a yankunan da ke fama da cutar kansar ƙwayoyin cuta ta B-cell. Lymphoma na B-Cell (DLBCL) da kuma ƙwayoyin cutar B-cell marasa aiki. Wannan bincike mai ban mamaki, wanda aka buga a cikinMujallar Ciwon Kankara ta Asibiti, ya nuna cewa maganin CAR-T zai iya zama babban ci gaba ga marasa lafiya waɗanda suka gaji da zaɓuɓɓukan magani na gargajiya.

A cikin binciken, an yi wa rukunin marasa lafiya 15 da ke fama da cutar B-cell magani bayan sun sami tsarin maganin chemotherapy mai kyau. Abin mamaki, sama da rabin waɗannan marasa lafiya sun sami cikakkiyar sassauci (CR), ciki har da huɗu daga cikin bakwai da za a iya kimantawa da ke fama da cutar DLBCL mai hana chemotherapy. Sakamakon yana da matuƙar kyau, inda wasu marasa lafiya ke ci gaba da kula da CR har zuwa watanni 22.

Maganin CAR-T yana aiki ta hanyar gyara ƙwayoyin T na majiyyaci don bayyana mai karɓar CD19, wanda daga nan zai kai hari kuma ya lalata ƙwayoyin B masu ciwon daji. Binciken ya lura cewa wannan hanyar ba wai kawai ta kasance mai yiwuwa ba, har ma tana da matuƙar tasiri wajen samar da sassauci mai ɗorewa. Duk da haka, maganin bai kasance ba tare da ƙalubale ba. An lura da guba mai tsanani, kamar su cutar sakin cytokine da gubar jijiyoyi, kodayake galibi ana iya magance su kuma an magance su cikin 'yan makonni.

Dr. J. Kochenderfer, ɗaya daga cikin manyan masu binciken, ya jaddada mahimmancin waɗannan binciken, yana mai cewa, "Wannan shine rahoto na farko na nasarar maganin DLBCL tare da ƙwayoyin CAR-T masu hana CD19, kuma yana buɗe ƙofa don ci gaba da haɓaka wannan hanyar."

Binciken da aka gudanar a wannan binciken ya ba da sabon bege ga marasa lafiya da ke fama da cutar sankarar B-cell lymphomas, waɗanda a da ba su da zaɓuɓɓukan magani da kuma mummunan hasashen da za su iya faruwa. Yayin da maganin CAR-T ke ci gaba da bunƙasa, yana iya zama magani na yau da kullun ga nau'ikan cututtukan ƙwayoyin B daban-daban, yana ba da damar tsira ga waɗanda ke fama da waɗannan cututtukan daji masu tsanani.